Abstract
Purpose. To compare, in a clinical study of a special design, the pharmacokinetic profile of mirtazapine in 20 young healthy male volunteers on two treatment regimens with homothetic oral tablets at steady state: NOCTE (1 × 30 mg at 21.00 h) and BID (15 mg at 21.00 h and 15 mg at 09.00 h).
Methods. Pharmacokinetic parameters were calculated from mirtazapine plasma levels assayed by gas chromatography with nitrogen-sensitive detection. A special analysis of variance allowed interesting interactions to be distinguished.
Results. The steady state was reached after 4 and 6 days for NOCTE and BID respectively; the difference was presumably due to intersubject variability. In accordance with pharmacokinetic theory, the peak-to-trough ratio at steady state was significantly lower (twofold) for BID than for NOCTE. Within BID, a small difference (approx. 10%) was found in the extent of absorption between evening and morning administration. Although statistically significant, this difference meets strict bioequivalence requirements. The regimens NOCTE and BID were found to be bioequivalent for the steady-state area-under-the-curve-curve and the peak time. Bioequivalence testing for the peak level was not meaningful due to the difference in dosing regimens. The observed elimination half-lives of 19.7 ± 3.0 h and 20.8 ± 2.7 h (n = 20) for NOCTE and BID, respectively are in agreement with previous results.
Conclusions. Differences (if any) were found to meet strict bioequivalence requirements and were so small that they are of no clinical consequence.
Similar content being viewed by others
REFERENCES
T. de Boer, F. Nefkens, and A. van Helvoirt. Eur. J. Pharmacol. 253:R5–6, 1994.
T. de Boer and G. S. F. Ruigt. CNS Drugs 4:(Suppl 1), 29–38, 1995.
C. de Montigny, N. Haddjeri, R. Mongeau, and P. Blier. CNS Drugs 4:(Suppl 1), 13–17, 1995.
G. Voortman and J. E. Paanakker. Human Psychopharmacol. 10:(Suppl 2), S83–96, 1995.
C. J. Timmer, A. Lohmann and C. P. A. Mink. Human Psychopharmacol. 10:(Suppl 2), S97–106, 1995.
C. J. Timmer, J. E. Paanakker and H. J. M. van Hal. Human Psychopharmacol., in press.
F. M. Kaspersen, A. A. M. van Rooij, E. G. M. Sperling, and J. H. Wieringa. J. Lab. Comp. Radiopharm. 27:1055–1068, 1989.
J. E. Paanakker and H. J. M. van Hal. J. Chromatogr. Biomed. Appl. 417:203–207, 1987.
U.S. Food and Drug Administration Guidance. Statistical procedures for bioequivalence testing using a standard two-treatment crossover design. Statement prepared by the Division of Bioequivalence, Office of Generic Drugs of the FDA, informal communication under 21 CFR 10.90, 1992.
Commission on the European Communities, Committee for Proprietary Medicinal Products CPMP. Note for Guidance, Investigation of Bioavailability and Bioequivalence, III/54/89-EN, 1991.
K. K. Midha, E. D. Ormsby, J. W. Hubbard, G. McKay, E. M. Hawes, L. Gavalas, and I. J. McGilveray. J. Pharm. Sci. 82:138–144, 1993.
D. J. Schuirmann. J. Pharmacokin. Biopharm. 15:657–680, 1987.
B. J. Winer. Statistical principles in experimental design, 2nd Ed., McGraw-Hill, New York, 1971, pp. 851–853.
H. P. Wijnand. Comp. Meth. Progr. Biomedicine 49:249–259, 1993.
SAS Institute Inc. SAS User's Guide, Version 5.16, SAS Institute Inc., Cary, N.C., U.S.A., 1987.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Timmer, C.J., Paanakker, J.E. & Vrijmoed-de Vries, M. Mirtazapine Pharmacokinetics with Two Dosage Regimens and Two Pharmaceutical Formulations. Pharm Res 14, 98–102 (1997). https://doi.org/10.1023/A:1012067703764
Issue Date:
DOI: https://doi.org/10.1023/A:1012067703764